Matuzumab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), which is involved in the regulation of cell growth and differentiation. This therapeutic agent is primarily investigated for its potential use in treating various types of cancers, particularly those characterized by overexpression of EGFR. Matuzumab functions by binding to the extracellular domain of the EGFR, inhibiting its activation and subsequent signaling pathways that promote tumor growth and survival. The antibody is designed to enhance the immune response against cancer cells and may be used in combination with other treatments to improve efficacy. As a biologic drug, matuzumab is produced through recombinant DNA technology and is subject to rigorous testing for safety and effectiveness in clinical trials. Its pharmacokinetics, including absorption, distribution, metabolism, and excretion, are influenced by factors such as the patient's immune response and the presence of other medications. Overall, matuzumab represents a targeted approach in cancer therapy, aiming to minimize damage to healthy tissues while maximizing therapeutic effects on malignant cells.

Matuzumab

339186-68-4: Matuzumab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), which is involved in the regulation of cell growth and differentiation. This therapeutic agent is primarily investigated for its potential use in treating various types of cancers, particularly those characterized by overexpression of EGFR. Matuzumab functions by binding to the extracellular domain of the EGFR, inhibiting its activation and subsequent signaling pathways that promote tumor growth and survival. The antibody is designed to enhance the immune response against cancer cells and may be used in combination with other treatments to improve efficacy. As a biologic drug, matuzumab is produced through recombinant DNA technology and is subject to rigorous testing for safety and effectiveness in clinical trials. Its pharmacokinetics, including absorption, distribution, metabolism, and excretion, are influenced by factors such as the patient's immune response and the presence of other medications. Overall, matuzumab represents a targeted approach in cancer therapy, aiming to minimize damage to healthy tissues while maximizing therapeutic effects on malignant cells.

Matuzumab (EMD 72000) is a humanized monoclonal antibody targeting EGFR that can be used to study non-small cell lung cancer.

<p>Intereferes with EGFR homodimerisation; cancer therapy</p>

CAS 339186-68-4

Matuzumab

Matuzumab

Ref: TM-T9922

Matuzumab - 10 mg/ml

Ref: 3D-BM165590